Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response

[1]  F. Turkheimer,et al.  N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study , 2021, European Neuropsychopharmacology.

[2]  A. Egerton,et al.  Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia , 2021, Schizophrenia bulletin.

[3]  N. Vanchakova,et al.  Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics , 2017, Brain Research.

[4]  F. Turkheimer,et al.  Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. , 2016, Schizophrenia bulletin.

[5]  W. Schultz.  Neuronal Reward and Decision Signals: From Theories to Data. , 2015, Physiological reviews.

[6]  O. Howes,et al.  Glutamate and dopamine in schizophrenia: An update for the 21st century , 2015, Journal of psychopharmacology.

[7]  S. Kapur,et al.  A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). , 2014, The British journal of psychiatry : the journal of mental science.

[8]  R. Murray,et al.  Schizophrenia: an integrated sociodevelopmental-cognitive model , 2014, The Lancet.

[9]  L. Krabbendam,et al.  Reduced brain reward response during cooperation in first-degree relatives of patients with psychosis: an fMRI study , 2014, Psychological Medicine.

[10]  Daeyeol Lee,et al.  Cortical Signals for Rewarded Actions and Strategic Exploration , 2013, Neuron.

[11]  Lydia Krabbendam,et al.  Trust versus paranoia: abnormal response to social reward in psychotic illness. , 2013, Brain : a journal of neurology.

[12]  S. Shergill,et al.  When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia , 2013, British Journal of Psychiatry.

[13]  R. Murray,et al.  Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. , 2012, The American journal of psychiatry.

[14]  Brooks King-Casas,et al.  Understanding Interpersonal Function in Psychiatric Illness Through Multiplayer Economic Games , 2012, Biological Psychiatry.

[15]  J. Libiger,et al.  Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. , 2012, Journal of psychiatric research.

[16]  S. Yamamura,et al.  Clozapine, but not haloperidol, enhances glial d‐serine and L‐glutamate release in rat frontal cortex and primary cultured astrocytes , 2012, British journal of pharmacology.

[17]  J. Kane.  Addressing nonresponse in schizophrenia. , 2012, The Journal of clinical psychiatry.

[18]  Abraham Z. Snyder,et al.  Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion , 2012, NeuroImage.

[19]  G. Barker,et al.  Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology , 2012, Molecular Psychiatry.

[20]  Christopher J. Peck,et al.  Reward Modulates Attention Independently of Action Value in Posterior Parietal Cortex , 2009, The Journal of Neuroscience.

[21]  P. McGuire,et al.  Functional neuroimaging in schizophrenia: diagnosis and drug discovery. , 2008, Trends in pharmacological sciences.

[22]  Benoit Dawant,et al.  Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine , 2006, Neuropsychopharmacology.

[23]  Evan M. Gordon,et al.  Neural Signatures of Economic Preferences for Risk and Ambiguity , 2006, Neuron.

[24]  S. Kapur,et al.  From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.

[25]  S. Quartz,et al.  Getting to Know You: Reputation and Trust in a Two-Person Economic Exchange , 2005, Science.

[26]  D. Weinberger,et al.  Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.

[27]  M. Platt,et al.  Expectations and outcomes: decision-making in the primate brain , 2005, Journal of Comparative Physiology A.

[28]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  S. Woods,et al.  Chlorpromazine equivalent doses for the newer atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[30]  M. Roesch,et al.  Impact of expected reward on neuronal activity in prefrontal cortex, frontal and supplementary eye fields and premotor cortex. , 2003, Journal of neurophysiology.

[31]  W. Schultz.  Getting Formal with Dopamine and Reward , 2002, Neuron.

[32]  R. Conley,et al.  Management of treatment resistance in schizophrenia , 2001, Biological Psychiatry.

[33]  P. Buckley,et al.  Treatment-refractory schizophrenia , 2001, Current psychiatry reports.

[34]  S. Provencher.  Automatic quantitation of localized in vivo 1H spectra with LCModel , 2001, NMR in biomedicine.

[35]  Michael L. Platt,et al.  Neural correlates of decision variables in parietal cortex , 1999, Nature.

[36]  J D Brodie,et al.  Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. , 1998, The American journal of psychiatry.

[37]  T. Cooper,et al.  Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. , 1989, The American journal of psychiatry.

[38]  C. B. Drucker.  Decision-Making in the Primate Brain , 2016 .

[39]  S. Haber,et al.  The Reward Circuit: Linking Primate Anatomy and Human Imaging , 2010, Neuropsychopharmacology.

[40]  T. Cooper,et al.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function , 2005, Journal of Neural Transmission / General Section JNT.

[41]  H. Meltzer,et al.  Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. , 1997, The American journal of psychiatry.

[42]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.